|View printer-friendly version|
|INC Research Expands Infectious Diseases Team to Support Global Vaccine Development Research|
Dr. Frederick Young to Lead Company's Infectious Diseases Therapeutic Unit
Raleigh, N.C., April 24, 2012 - INC Research, LLC, a therapeutically focused clinical research organization (CRO) with a Trusted Process® for delivering reliable results, today announced Frederick Young, PhD, has joined its Infectious Diseases leadership team as vice president, Infectious Diseases. Dr. Young will leverage his extensive clinical research and development expertise to lead the Company's infectious diseases therapeutic unit globally.
"Antibiotics and other antimicrobials have played a critical role in the fight against infectious diseases, but further discovery and evaluation of new treatments is still needed," said Patricia Monteforte, executive vice president and general manager, General Medicine, INC Research. "We've become a leader in infectious diseases research by having a therapeutically-focused team with experience in all stages and disciplines associated with the development of anti-infectives. With the addition of Frederick, INC Research is positioned to expand this therapeutic unit even further with experienced resources to support and advance our customers' research and development."
Prior to joining INC Research, Dr. Young was vice president of strategic programs at ICON, where he was a Strategic Account Program Leader and head of the Strategic Programs Group.. His experience also includes 12 years with Novartis in a number of positions of increasing responsibility, including clinical research scientist, executive director, project leader and vice president/global program head. Dr. Young received his undergraduate degree from Emory University, earned his doctorate in chemistry from Georgia Institute of Technology and was awarded a master's degree in business administration from Rutgers University.
INC Research's Infectious Disease team has experience in all stages of infectious disease research from initial clinical plan development to Phase I through Phase IV study conduct to the filing of INDs, NDAs, sNDAs and ex-U.S. submissions. The team's experience spans both pediatric and adult trials of all levels of complexity, from Phase I to highly-complex Phase II and III clinical trials, and from treating everyday infections to fighting highly-resistant pathogens in an intensive care setting. For more information on INC Research's therapeutic expertise in Infectious Diseases, click here. To read therapeutic case studies on infectious diseases, click here.
About INC Research
INC Research is a therapeutically focused clinical research organization with a high-performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in all therapeutic areas and innovative pediatric and women's health trials. The Company's Trusted Process® methodology and therapeutic foresight lead customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, NC. For more information, please visit www.incresearch.com or follow us at @inc_research.
CONTACT: Lori Dorer, Media, (513) 345-1685